MCID: HYP073
MIFTS: 43

Hypersensitivity Reaction Type Iv Disease malady

Categories: Cancer diseases, Immune diseases

Aliases & Classifications for Hypersensitivity Reaction Type Iv Disease

Aliases & Descriptions for Hypersensitivity Reaction Type Iv Disease:

Name: Hypersensitivity Reaction Type Iv Disease 12 14
Immunoproliferative Disorders 42 69
Immunoproliferative Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2916
ICD10 33 C88.9 C88
MeSH 42 D007160
UMLS 69 C0021070

Summaries for Hypersensitivity Reaction Type Iv Disease

MalaCards based summary : Hypersensitivity Reaction Type Iv Disease, also known as immunoproliferative disorders, is related to sarcoidosis 1 and autoimmune lymphoproliferative syndrome. An important gene associated with Hypersensitivity Reaction Type Iv Disease is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Asparaginase and Cladribine have been mentioned in the context of this disorder. Related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Hypersensitivity Reaction Type Iv Disease

Diseases in the Hypersensitivity Reaction Type Ii Disease family:

Hypersensitivity Reaction Type Iii Disease Hypersensitivity Reaction Type Iv Disease

Diseases related to Hypersensitivity Reaction Type Iv Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
id Related Disease Score Top Affiliating Genes
1 sarcoidosis 1 11.0
2 autoimmune lymphoproliferative syndrome 11.0
3 heavy chain disease 11.0
4 cryoglobulinemia 11.0
5 lymphoid interstitial pneumonia 11.0
6 tuberculous pneumothorax 10.4 ACE CD40LG
7 alcoholic neuropathy 10.4 CD40LG CD79A
8 hypercalcemic sarcoidosis 10.4 ACE LYZ
9 camptodactyly vertebral fusion 10.4 CD40LG CD79A
10 spinal polio 10.3 CD40LG CD79A
11 rabies 10.3 CD40LG CD79A
12 unilateral retinoblastoma 10.3 CD40LG CD79A
13 hordeolum 10.3 CD40LG SMUG1
14 mesangial proliferative glomerulonephritis 10.3 CD40LG CD79A
15 delta chain disease 10.3 CD40LG CD79A
16 glomangiosarcoma 10.3 CD40LG CD79A MYOM2
17 loeffler syndrome 10.3 CD79A LYZ
18 discitis 10.3 CD40LG CD79A
19 arteriosclerosis 10.3 CD40LG CD79A MYOM2
20 spinal canal and spinal cord meningioma 10.3 CD40LG CD79A
21 endobronchial lipoma 10.3 ACE CD40LG LYZ
22 trichostrongyloidiasis 10.3 CD40LG CD79A
23 ethmoid sinus schneiderian papilloma 10.3 CD40LG CD79A MYOM2
24 angiokeratoma 10.3 CD40LG CD79A LYZ
25 artery disease 10.3 CD40LG CD79A SMUG1
26 basal ganglia disease 10.3 CD40LG CD79A SMUG1
27 gastroduodenal crohn's disease 10.3 CD40LG CD79A TNF
28 glycogen storage disease viii 10.3 CD40LG CD79A LYZ
29 postinflammatory pulmonary fibrosis 10.3 CD40LG CD79A LYZ
30 dermatomycosis 10.3 CD40LG CD79A TNF
31 heart septal defect 10.3 CD40LG CD79A
32 sarcomatoid squamous cell skin carcinoma 10.3 SMUG1 TNFRSF1B
33 tall cell variant papillary carcinoma 10.3 CD40LG CD79A MYOM2
34 peripheral artery disease 10.3 ACE MYOM2 TNF
35 rickettsialpox 10.3 CD40LG CD79A TNF
36 cutaneous polyarteritis nodosa 10.3 CD40LG CD79A
37 pseudohypoparathyroidism 10.3 CD40LG CD79A FAS
38 radial hypoplasia, triphalangeal thumbs and hypospadias 10.3 CD40LG CD79A TNF
39 dermatosis papulosa nigra 10.3 ACE NOD2 TNF
40 disease of mental health 10.3 CD40LG CD79A TNF
41 cardiac sarcoidosis 10.2 ACE TNF TNFRSF1B
42 mixed germ cell-sex cord neoplasm 10.2 ACE CD40LG CD79A
43 venezuelan equine encephalitis 10.2 CD40LG CD79A MYOM2 SMUG1
44 mammary paget's disease 10.2 LYZ SMUG1 TNFRSF1B
45 basilar artery occlusion 10.2 CD40LG CD79A MRAP
46 vulvovaginal candidiasis 10.2 CD40LG CD79A MRAP
47 st. louis encephalitis 10.2 CD40LG IL2 MYOM2
48 hairy tongue 10.2 CD40LG CD79A MRAP
49 childhood pleomorphic rhabdomyosarcoma 10.2 CD40LG CD79A MYOM2 TNF
50 pancreatic serous cystadenoma 10.2 CD40LG CD79A MRAP

Graphical network of the top 20 diseases related to Hypersensitivity Reaction Type Iv Disease:



Diseases related to Hypersensitivity Reaction Type Iv Disease

Symptoms & Phenotypes for Hypersensitivity Reaction Type Iv Disease

GenomeRNAi Phenotypes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ACE CD40LG FAS IL2 NOD2 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CD40LG FAS IL2 NOD2 TNF TNFRSF1B

MGI Mouse Phenotypes related to Hypersensitivity Reaction Type Iv Disease:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 CD8A FAS IL1RN IL2 LYZ NOD2
2 hematopoietic system MP:0005397 10.25 CD4 CD40LG CD79A CD8A FAS IL1RN
3 homeostasis/metabolism MP:0005376 10.22 SMUG1 TLR9 TNF TNFRSF1B ACE CD4
4 immune system MP:0005387 10.18 ACE CD4 CD40LG CD79A CD8A FAS
5 endocrine/exocrine gland MP:0005379 10.11 CD8A FAS IL2 LYZ TNF TNFRSF1B
6 digestive/alimentary MP:0005381 10.08 CD4 FAS IL2 LYZ NOD2 TLR9
7 mortality/aging MP:0010768 9.97 ACE CD4 CD40LG CD8A FAS IL1RN
8 integument MP:0010771 9.92 CD4 CD40LG CD8A FAS IL1RN LYZ
9 liver/biliary system MP:0005370 9.8 ACE CD79A FAS IL2 LYZ TNF
10 neoplasm MP:0002006 9.56 ACE CD79A FAS IL2 LYZ SMUG1
11 renal/urinary system MP:0005367 9.17 ACE CD40LG CD79A FAS LYZ TLR9

Drugs & Therapeutics for Hypersensitivity Reaction Type Iv Disease

Drugs for Hypersensitivity Reaction Type Iv Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 984)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Asparaginase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 9015-68-3
2
Cladribine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4291-63-8 20279
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
4
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 147-94-4 6253
5
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 20830-81-3 30323
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
7
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
8
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
9
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 21679-14-1, 75607-67-9 30751
10
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
11
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1959-05-2, 59-05-2 126941
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
14
Teniposide Approved Phase 4,Phase 3,Phase 2,Phase 1 29767-20-2 34698
15
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1 154-42-7 2723601
16
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2068-78-2, 57-22-7 5978
17
Vindesine Approved Phase 4,Phase 3,Phase 2,Phase 1 59917-39-4, 53643-48-4 40839
18
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 130167-69-0
19
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 174722-31-7 10201696
20
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
21
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 3778-73-2 3690
22
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
23
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
24
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53910-25-1 40926 439693
25
Amlodipine Approved Phase 4 88150-42-9 2162
26
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
27
Ethanol Approved Phase 4,Phase 2,Phase 1 64-17-5 702
28
Linagliptin Approved Phase 4,Phase 2 668270-12-0 10096344
29
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
30
Voglibose Approved, Investigational Phase 4 83480-29-9 444020
31
Arsenic trioxide Approved, Investigational Phase 4,Phase 2,Phase 1 1327-53-3 518740
32
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24356-66-9 32326 21704
33
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 65271-80-9 4212
34
Denileukin diftitox Approved, Investigational Phase 4,Phase 2,Phase 1 173146-27-5
35
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
36
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55-98-1 2478
37
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 179324-69-7 387447 93860
38
Entecavir Approved, Investigational Phase 4,Phase 2 142217-69-4 153941
39
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
40
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
41
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-23-7 5754 657311
42
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1 148-82-3 4053 460612
43
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
44
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
45
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
46
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 1 111025-46-8 4829
47
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
48
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
49
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2 274901-16-5 6918537
50
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983

Interventional clinical trials:

(show top 50) (show all 5450)
id Name Status NCT ID Phase
1 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4
2 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4
3 Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old. Unknown status NCT00429065 Phase 4
4 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4
5 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4
6 Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET Unknown status NCT00188149 Phase 4
7 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4
8 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4
9 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4
10 Lymphoma in the Orbit Unknown status NCT01302912 Phase 4
11 A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Unknown status NCT01184599 Phase 4
12 Rationale and Design for Shiga Microalbuminuria Reduction Trial Unknown status NCT00202618 Phase 4
13 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
14 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4
15 Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Unknown status NCT00196768 Phase 4
16 LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients Unknown status NCT02077257 Phase 4
17 Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) Completed NCT01088724 Phase 4
18 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4
19 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4
20 Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma Completed NCT01124526 Phase 4
21 Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Completed NCT00199004 Phase 4
22 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4
23 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Completed NCT00199056 Phase 4
24 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4
25 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4
26 Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4
27 Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia Completed NCT01457040 Phase 4
28 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4
29 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4
30 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4
31 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4
32 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms Completed NCT01164475 Phase 4
33 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4
34 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4
35 MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. Completed NCT00430352 Phase 4
36 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4
37 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4
38 Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma Completed NCT00090038 Phase 4
39 An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease. Completed NCT00440817 Phase 4
40 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4
41 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4
42 Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients Completed NCT00050999 Phase 4
43 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
44 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4
45 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4
46 Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients Completed NCT02108444 Phase 4
47 Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) Completed NCT01007448 Phase 4
48 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4
49 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
50 Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Completed NCT00051012 Phase 4

Search NIH Clinical Center for Hypersensitivity Reaction Type Iv Disease

Cochrane evidence based reviews: immunoproliferative disorders

Genetic Tests for Hypersensitivity Reaction Type Iv Disease

Anatomical Context for Hypersensitivity Reaction Type Iv Disease

Publications for Hypersensitivity Reaction Type Iv Disease

Variations for Hypersensitivity Reaction Type Iv Disease

Expression for Hypersensitivity Reaction Type Iv Disease

Search GEO for disease gene expression data for Hypersensitivity Reaction Type Iv Disease.

Pathways for Hypersensitivity Reaction Type Iv Disease

Pathways related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 33)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 BTNL2 CASP10 CD4 CD40LG CD79A CD8A
2
Show member pathways
13.31 CD4 CD40LG IL1RN IL2 NOD2 TNF
3
Show member pathways
13.24 CASP10 CD4 CD40LG FAS IL2 TNF
4
Show member pathways
12.83 CASP10 CD4 FAS TNF TNFRSF1B
5
Show member pathways
12.83 ACE CASP10 FAS IL2 TLR9 TNF
6
Show member pathways
12.77 CD4 CD40LG CD8A FAS IL2 TNF
7
Show member pathways
12.64 CD40LG IL2 TLR9 TNF TNFRSF1B
8
Show member pathways
12.58 CD4 CD40LG FAS TNF TNFRSF1B
9
Show member pathways
12.52 CASP10 CD40LG FAS TLR9 TNF TNFRSF1B
10
Show member pathways
12.49 CD4 CD40LG CD79A IL2 TNF TNFRSF1B
11
Show member pathways
12.29 CD4 CD40LG CD8A FAS IL2 TNF
12
Show member pathways
12.27 CASP10 FAS TNF TNFRSF1B
13 12.17 CASP10 NOD2 TLR9 TNF
14
Show member pathways
11.85 CD4 IL2 TLR9 TNF
15 11.83 CD4 CD79A CD8A IL2 TNF
16 11.77 CD40LG CD79A CD8A FAS IL1RN IL2
17
Show member pathways
11.71 CD40LG IL2 TNF
18
Show member pathways
11.71 CD40LG FAS TNF TNFRSF1B
19
Show member pathways
11.69 CD40LG TNF TNFRSF1B
20 11.66 CD40LG TLR9 TNF
21 11.64 CD4 CD8A IL2 TNF
22
Show member pathways
11.6 CD40LG IL2 TNF
23 11.59 CASP10 FAS NOD2 TNF TNFRSF1B
24
Show member pathways
11.58 CD8A IL2 TNF
25 11.49 FAS IL2 TNF
26 11.46 IL1RN TNF TNFRSF1B
27 11.46 CD40LG TLR9 TNF
28 11.29 FAS TLR9 TNF
29 11.25 CD40LG IL2 TNFRSF1B
30 11.23 CD4 CD8A IL2 TLR9 TNF
31
Show member pathways
11.22 FAS IL2 TNF TNFRSF1B
32 11.19 CD4 IL2 TNF
33 11.13 CD4 CD40LG CD79A CD8A

GO Terms for Hypersensitivity Reaction Type Iv Disease

Cellular components related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 ACE CD40LG CD8A FAS IL1RN IL2
2 cell surface GO:0009986 9.63 CD4 CD40LG CD8A FAS NOD2 TNF
3 CD95 death-inducing signaling complex GO:0031265 9.37 CASP10 FAS
4 membrane raft GO:0045121 9.35 CD4 CD79A FAS TNF TNFRSF1B
5 external side of plasma membrane GO:0009897 9.17 ACE CD4 CD40LG CD79A CD8A FAS
6 plasma membrane GO:0005886 10.13 ACE BTNL2 CD4 CD40LG CD79A CD8A

Biological processes related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

(show all 22)
id Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.89 CASP10 FAS NOD2 TNFRSF1B
2 defense response to bacterium GO:0042742 9.88 LYZ NOD2 TLR9 TNF
3 immune system process GO:0002376 9.88 CD4 CD79A CD8A IL2 NOD2 TLR9
4 cell surface receptor signaling pathway GO:0007166 9.85 CASP10 CD4 CD79A CD8A TNFRSF1B
5 positive regulation of protein phosphorylation GO:0001934 9.84 CD4 FAS IL2 TNF
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.8 CD40LG NOD2 TLR9 TNF
7 tumor necrosis factor-mediated signaling pathway GO:0033209 9.78 CD40LG FAS TNF TNFRSF1B
8 response to glucocorticoid GO:0051384 9.76 FAS IL1RN TNF
9 positive regulation of JNK cascade GO:0046330 9.74 NOD2 TLR9 TNF
10 positive regulation of interleukin-6 production GO:0032755 9.7 NOD2 TLR9 TNF
11 extrinsic apoptotic signaling pathway GO:0097191 9.69 FAS TNF TNFRSF1B
12 apoptotic signaling pathway GO:0097190 9.62 CASP10 FAS TNF TNFRSF1B
13 positive regulation of interleukin-17 production GO:0032740 9.61 IL2 NOD2
14 positive regulation of interleukin-8 production GO:0032757 9.61 NOD2 TLR9 TNF
15 maintenance of gastrointestinal epithelium GO:0030277 9.6 NOD2 TLR9
16 necroptotic signaling pathway GO:0097527 9.56 FAS TNF
17 positive regulation of T cell proliferation GO:0042102 9.56 BTNL2 CD4 CD40LG IL2
18 regulation of immunoglobulin secretion GO:0051023 9.55 CD40LG TNF
19 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.55 CASP10 CD4 NOD2 TLR9 TNF
20 positive regulation of interleukin-10 production GO:0032733 9.54 CD40LG NOD2 TLR9
21 inflammatory response GO:0006954 9.5 CD40LG FAS IL1RN LYZ TLR9 TNF
22 immune response GO:0006955 9.23 CD4 CD40LG CD8A FAS IL1RN IL2

Molecular functions related to Hypersensitivity Reaction Type Iv Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.26 CD4 CD79A FAS TLR9
2 cytokine activity GO:0005125 8.92 CD40LG IL1RN IL2 TNF

Sources for Hypersensitivity Reaction Type Iv Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....